# A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

> **NCT03473743** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 125 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Erdafitinib
- **DRUG:** Cetrelimab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03473743
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-05
- **Primary completion:** 2022-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03473743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03473743, "A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03473743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*